October 18, 2022, 2pm EDT
Evotec recently hosted its Innovation Week webinar series - 5 virtual sessions over 5 days. Session 5 discusses Evotec’s capabilities for supporting all activities across the R&D continuum for biotherapeutics, i.e. Discovery and optimization of novel antibodies for specific disease targets, evaluation of lead antibodies for disease efficacy and safety, alongside process development and manufacturing
Monoclonal antibodies (mAbs) have become increasingly sophisticated over the past decades. This also holds true for the technologies enabling the identification, design, preclinical and manufacturing processes of monoclonal antibodies. While the traditional hybridoma technology is still broadly used for the creation of mAbs, novel technologies such as immune antibody libraries or fully humanoid antibody libraries have emerged in recent years. Moreover, researchers can today leverage a range of powerful approaches to optimize the mAb creation process, e.g., high-throughput screening, state-of-the-art sequencing, AI/machine learning or analytics. This webinar covers Evotec´s capabilities for supporting all activities across the R&D continuum,
Discovery and optimization of novel antibodies for specific disease targets
Evaluation of lead antibodies for disease efficacy and safety
Process development and manufacturing
Key Learning Objectives:
Learn how Evotec can help you with less expensive, faster and more flexible ways of discovering, developing and manufacturing biotherapeutics.
Gain insight in the most up-to-date methods to optimize antibody development and manufacturing
Understand how AI to can help solve problems before they occur
Function: Research, Business Development, Consulting
Barbara Bachler-Konetzki Group Leader, In Vitro Pharmacology Evotec SE
Barbara is a Group Leader in the In vitro pharmacology department at Evotec in Hamburg, Germany.
Joining Evotec in 2018, she played a key role in the establishment of the streamlined hybridoma platform and the implementation of the ATX-Gx™ mice from Alloy as source of fully human antibodies.
She is now leading a group of scientists and technicians supporting internal and external antibody programs from target identification to candidate nomination and serves as the therapeutic area head for fully integrated biologics projects at Evotec.
Senior Vice President of Biotherapeutic Discovery and Molecular Design at Just - Evotec Biologics, an Evotec Seattle-based subsidiary
24 years of experience in biologics discovery, design, and development
Responsible at Just - Evotec Biologics for J.HAL discovery, biologics modality design, antibody humanization and developability optimization, bioinformatics platforms, and data sciences
Maria Pilla EVP Global Head of Preclinical Development Evotec SE
Executive Vice President Head of Global Preclinical Development business unit.
We take care of the design and performance all the preclinical studies required by regulatory authorities to enable FIM, as well as supporting the choice of the safest candidate in earlier phases of discovery/development.
The team includes all the critical disciplines necessary to accomplish this, ensuring efficiency and smooth problem solving